Threshold Pharmaceuticals Inc. (NASDAQ:THLD)‘s stock had its “outperform” rating reaffirmed by equities research analysts at William Blair in a research note issued to investors on Monday.
Separately, S&P Equity Research reduced their price target on shares of Threshold Pharmaceuticals from $0.67 to $0.52 in a research report on Friday. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $7.26.
Threshold Pharmaceuticals (NASDAQ:THLD) traded down 1.11% during midday trading on Monday, hitting $0.67. The company’s stock had a trading volume of 1,535,319 shares. Threshold Pharmaceuticals has a 12 month low of $0.21 and a 12 month high of $4.44. The company’s 50 day moving average price is $1.06 and its 200 day moving average price is $0.62. The firm has a market cap of $47.91 million, a P/E ratio of 1.13 and a beta of 3.98.
Threshold Pharmaceuticals (NASDAQ:THLD) last released its earnings results on Monday, August 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.10). Analysts expect that Threshold Pharmaceuticals will post ($0.38) EPS for the current year.
Large investors have recently made changes to their positions in the stock. Oxford Asset Management increased its stake in shares of Threshold Pharmaceuticals by 746.7% in the second quarter. Oxford Asset Management now owns 202,522 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 178,602 shares during the period. Paloma Partners Management Co bought a new stake in Threshold Pharmaceuticals during the second quarter worth approximately $152,000. Renaissance Technologies LLC increased its stake in Threshold Pharmaceuticals by 55.5% in the first quarter. Renaissance Technologies LLC now owns 1,016,764 shares of the biotechnology company’s stock worth $468,000 after buying an additional 363,100 shares during the period. Adage Capital Partners GP L.L.C. increased its stake in Threshold Pharmaceuticals by 16.7% in the first quarter. Adage Capital Partners GP L.L.C. now owns 3,500,000 shares of the biotechnology company’s stock worth $1,610,000 after buying an additional 500,000 shares during the period. Finally, Deerfield Management Co. bought a new stake in Threshold Pharmaceuticals during the second quarter worth approximately $1,641,000. 28.22% of the stock is owned by institutional investors.
About Threshold Pharmaceuticals
Threshold Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.
Receive News & Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.